Amneal Pharmaceuticals (AMRX) EBITDA Margin (2017 - 2026)

Amneal Pharmaceuticals' EBITDA Margin history runs 10 years deep, the most recent figure standing at 19.62% for Q1 2026.

• On a quarterly basis, EBITDA Margin rose 519.0% year-over-year to 19.62% in Q1 2026; TTM through Mar 2026 was 14.3%, a 156.0% increase from a year earlier, with the FY2025 full-year figure at 13.05%, up 413.0% from the prior year.
• EBITDA Margin improved to 19.62% in Q1 2026 per AMRX's latest filing, from 13.76% in the prior quarter.
• Across five years, EBITDA Margin topped out at 19.62% in Q1 2026 and bottomed at 35.51% in Q2 2022.
• The 5-year median for EBITDA Margin is 10.38% (2024), against an average of 6.18%.
• Across the five-year window, EBITDA Margin sank 4805 bps in 2022 and surged 4888 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 8.72% in 2022, then jumped by 126 bps to 2.3% in 2023, then soared by 351 bps to 10.38% in 2024, then jumped by 33 bps to 13.76% in 2025, then jumped by 43 bps to 19.62% in 2026.
• Per Business Quant, the three latest AMRX EBITDA Margin figures stand at 19.62% (Q1 2026), 13.76% (Q4 2025), and 8.97% (Q3 2025).